{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:28:11Z","timestamp":1788672491140,"version":"build-2803163510"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to compare the effectiveness and tolerability between oral MTX and s.c. MTX in a large group of RA patients in a real-life setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this retrospective cohort study, adult patients with clinical diagnosis of RA who started MTX treatment (monotherapy or combined with HCQ) started with either oral or s.c. MTX. The primary outcome was superiority testing of between group difference in change in DAS28CRP between baseline and 3\u20136\u2009months, and subsequent non-inferiority (non-inferiority margin 0.6) testing analyses in case of non-superiority. Secondary outcomes included MTX dose, side effects, laboratory abnormalities and use of comedication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six hundred and forty RA patients were included: 259 started with oral MTX and 381 with s.c. MTX. There was no significant difference in \u0394DAS28CRP [after adjusting for confounding, 0.13 (95% CI: \u20130.14, 0.40)], and oral MTX strategy was non-inferior to s.c. The mean MTX dose was slightly lower for the oral strategy [18.0 (6.9) vs 19.9 (8.2), P\u2009=\u20090.002], which was accompanied by a lower cumulative incidence of adverse events (41% vs 52%, P\u2009=\u20090.005). No differences were seen in use of other comedication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Starting with oral MTX in RA in a real-life setting is non-inferior to a s.c. MTX treatment with regard to disease activity control, at least when used in dosages up to 25\u2009mg and on a background of HCQ co-treatment and a treat-to-target approach. In addition, tolerability was better. This supports the strategy of starting with oral MTX.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab313","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T03:13:53Z","timestamp":1617160433000},"page":"331-336","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness and tolerability of oral <i>vs<\/i> subcutaneous methotrexate in patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"61","author":[{"given":"Janne","family":"Heuvelmans","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"den Broeder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A H","family":"van den Elsen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons A","family":"den Broeder","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands"},{"name":"Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J F","family":"van den Bemt","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands"},{"name":"Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"2022010903451251900_keab313-B1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022010903451251900_keab313-B2","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/ijms20205023","article-title":"Methotrexate an old drug with new tricks","volume":"20","author":"Bedoui","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2022010903451251900_keab313-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022010903451251900_keab313-B4","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515 mg may be overcome with subcutaneous administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022010903451251900_keab313-B5","first-page":"563","article-title":"Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate","volume":"32","author":"Pichlmeier","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022010903451251900_keab313-B6","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J Rheumatol"},{"key":"2022010903451251900_keab313-B7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/ph5080802","article-title":"Involvement of multiple transporters-mediated transports in mizoribine and methotrexate pharmacokinetics","volume":"5","author":"Murakami","year":"2012","journal-title":"Pharmaceuticals (Basel)"},{"key":"2022010903451251900_keab313-B8","first-page":"272","article-title":"Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review","volume":"33","author":"Goodman","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2022010903451251900_keab313-B9","first-page":"481","article-title":"Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis","volume":"33","author":"Hoekstra","year":"2006","journal-title":"J Rheumatol"},{"key":"2022010903451251900_keab313-B10","doi-asserted-by":"crossref","first-page":"e0221823","DOI":"10.1371\/journal.pone.0221823","article-title":"Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis","volume":"14","author":"Bujor","year":"2019","journal-title":"PLoS One"},{"key":"2022010903451251900_keab313-B11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022010903451251900_keab313-B12","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","article-title":"The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis","volume":"75","author":"Hazlewood","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022010903451251900_keab313-B13"},{"key":"2022010903451251900_keab313-B14","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa580","article-title":"Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial","author":"Westhovens","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab313\/37910733\/keab313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/1\/331\/41929243\/keab313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/1\/331\/41929243\/keab313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T03:46:57Z","timestamp":1641700017000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/1\/331\/6206787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2021,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab313","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,3,31]]}}}